Skip to main content

Portfolio

Investment Principles
Investment Area
Investment Process
Portfolio
Project title
Research institute
Preclinical
Phase1
Phase2
Phase3
Licensure
Inactivated Rotavirus Vaccine
●
Schistosomiasis Vaccine
●
●
Typhoid Conjugate Vaccine
●
●
Measles-Rubella MAP Vaccine
●
Group A Streptococcus Vaccine
●
Technology Transfer of Pentavalent Meningitis Conjugate Vaccine
●
●
●
Pentavalent Meningococcal Conjugate vaccine
●
●
●
Non-replicating Protein Nanoparticle-based Rotavirus Vaccine
●
Novel Cholera Conjugate Vaccine
●
Manufacturing Process development for an inactivated Rotavirus Vaccine using attenuated CDC-9 strain
Development stage:
Phase1
Schistosomiasis Vaccine
Development stage:
Phase1, Phase2
Typhoid Conjugate Vaccine
Development stage:
Phase2, Phase3
Measles-Rubella MAP Vaccine
Development stage:
Preclinical
Group A Streptococcus Vaccine
Development stage:
Preclinical
Technology Transfer of Pentavalent Meningitis Conjugate Vaccine
Development stage:
Phase2, Phase3, Licensure
Pentavalent Meningococcal Conjugate vaccine
Development stage:
Phase2, Phase3, Licensure
Non-replicating Protein Nanoparticle-based Rotavirus Vaccine
Development stage:
Preclinical
Novel Cholera Conjugate Vaccine
Development stage:
Phase2
Project title
Research institute
Preclinical
Phase1
Phase2
Phase3
Licensure
Oxfendazole tablet formulation for Onchocerciasais
Continuous Manufacturing Process for Human Use Helminth Infection Treatment
●
●
Novel Antibiotic Combinations to Address AMR Burden in Neonatal Sepsis
●
●
Treatment Development for Severe Malaria
●
Oxfendazole tablet formulation for Onchocerciasais
Development stage :
Other (Formulation development)
Continuous Manufacturing Process for Human Use Helminth Infection Treatment
Development stage :
Phase2, Phase3
Novel Antibiotic Combinations to Address AMR Burden in Neonatal Sepsis
Development stage :
Phase3, Licensure
Treatment Development for Severe Malaria
Development stage :
Phase1
*WHO licensure prequalification
Project title
Research institute
Early Prototype Development/ Analytical Validation
Clinical Validation/ Usability Assessment
Licensure
Quantitative G6PD test
●
●
AI-driven All-in-one Diagnostic Platform for Malaria Species Differentiation
●
●
POCT for COVID19, Influenza and RSV
●
●
POCT for Multidrug-Resistant TB
●
Rapid Diagnostic Test for Malaria Antigen
●
POCT for Sexually Transmitted Infections and Resistance
●
●
●
Handheld POCT for Sexually Transmitted Infections
●
POCT for Sexually Transmitted Infections
●
Rapid Diagnostic Test for Malaria Detection in Saliva Samples
●
●
Quantitative G6PD test
Development stage:
Clinical Validation/ Usability Assessment
AI-driven All-in-one Diagnostic Platform for Malaria Species Differentiation
Development stage:
Clinical Validation/ Usability Assessment, Licensure
POCT for COVID19, Influenza and RSV
Development stage:
Clinical Validation/ Usability Assessment
POCT for Multidrug-Resistant TB
Development stage:
Clinical Validation/ Usability Assessment
Rapid Diagnostic Test for Malaria Antigen
Development stage:
Clinical Validation/ Usability Assessment
POCT for Sexually Transmitted Infections and Resistance
Development stage:
Clinical Validation/ Usability Assessment
Handheld POCT for Sexually Transmitted Infections
Development stage:
Early Prototype Development/ Analytical Validation
POCT for Sexually Transmitted Infections
Development stage:
Early Prototype Development/ Analytical Validation
Rapid Diagnostic Test for Malaria Detection in Saliva Samples
Development stage:
Clinical Validation/ Usability Assessment
No information yet.
Project title
Research institute
Study Area / Country
Analyzing Digital Solutions for Health System Gaps in Crisis-Affected Areas
Ethiopia, Nepal, Kiribati
Quantifying the Added Value of Lunit Software in Advancing TB Elimination Efforts
Vietnam
Understanding the End-user Perspectives of Implementing TB-CAD in High TB Burden Settings and Improving Fitness-for-Use in Children
Mongolia, Vietnam
Analyzing Digital Solutions for Health System Gaps in Crisis-Affected Areas
Study Area / Country :
Ethiopia, Nepal, Kiribati
Quantifying the Added Value of Lunit Software in Advancing TB Elimination Efforts
Study Area / Country :
Vietnam
Understanding the End-user Perspectives of Implementing TB-CAD in High TB Burden Settings and Improving Fitness-for-Use in Children
Study Area / Country :
Vietnam, Mongolia

Receive RfP updates from the RIGHT Foundation by e-mail